Search research articles
Contact Us
Filters
Showing results (781-790 of 1,060) with videos related to
Page
of 106
Sort By:
JAMA Cardiology
|
July 21, 2016
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
Thomas A Gaziano, Gregg C Fonarow, Brian Claggett, et al.
Lancet (London, England)
|
August 31, 2012
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D Solomon, Michael Zile, Burkert Pieske, et al.
European Journal of Heart Failure
|
May 16, 2014
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)
John J V McMurray, Milton Packer, Akshay S Desai, et al.
European Journal of Heart Failure
|
February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
Adriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 19, 1999
Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry
J H McElmurray, R Mukherjee, R B New, et al.
BMC Genomics
|
January 8, 2025
Genomic characterization of Escherichia coli with a polyketide synthase (pks) island isolated from ulcerative colitis patients
Chao Lv, Mohd Abdullah, Chun-Li Su, et al.
Circulation. Heart Failure
|
July 14, 2011
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy
Henry Krum, Maros Elsik, Hans G Schneider, et al.
Circulation. Heart Failure
|
January 13, 2016
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study
Michael R Zile, Pardeep S Jhund, Catalin F Baicu, et al.
European Journal of Heart Failure
|
January 26, 2022
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF
Maria A Pabón, Jonathan W Cunningham, Brian L Claggett, et al.
American Heart Journal
|
February 28, 2020
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)
James E Udelson, Gregory D Lewis, Sanjiv J Shah, et al.
Page
of 106
Search research articles
Search
Showing results (781-790 of 1,060) with videos related to
Sort By:
Page
of 106
JAMA Cardiology
|
July 21, 2016
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
Thomas A Gaziano, Gregg C Fonarow, Brian Claggett, et al.
Lancet (London, England)
|
August 31, 2012
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D Solomon, Michael Zile, Burkert Pieske, et al.
European Journal of Heart Failure
|
May 16, 2014
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)
John J V McMurray, Milton Packer, Akshay S Desai, et al.
European Journal of Heart Failure
|
February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
Adriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 19, 1999
Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry
J H McElmurray, R Mukherjee, R B New, et al.
BMC Genomics
|
January 8, 2025
Genomic characterization of Escherichia coli with a polyketide synthase (pks) island isolated from ulcerative colitis patients
Chao Lv, Mohd Abdullah, Chun-Li Su, et al.
Circulation. Heart Failure
|
July 14, 2011
Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy
Henry Krum, Maros Elsik, Hans G Schneider, et al.
Circulation. Heart Failure
|
January 13, 2016
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study
Michael R Zile, Pardeep S Jhund, Catalin F Baicu, et al.
European Journal of Heart Failure
|
January 26, 2022
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF
Maria A Pabón, Jonathan W Cunningham, Brian L Claggett, et al.
American Heart Journal
|
February 28, 2020
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF)
James E Udelson, Gregory D Lewis, Sanjiv J Shah, et al.
Page
of 106